Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 401–500 of 1,001
Tritos, N. A., Fazeli, P. K., McCormack, A. I., Mallea-Gil, S., Pineyro, M. M., Christ‐Crain, M., Frara, S., Labadzhyan, A., Ioachimescu, A. G., Shimon, I., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01170-3 · Cited by 23
The dopaminergic control of Cushing’s syndrome
Pivonello, R., Pivonello, C., Simeoli, C., Martino, M. C. D., & Colao, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01661-x · Cited by 23
“Nowadays, the guidelines for the treatment of hyperprolactinemia mainly recommend CAB as the treatment of choice to control circulating PRL levels and eventual lactotroph tumour growth, in case of PRL-secreting pituitary tumours [16].”
BackgroundThe metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations
Corona, G., Rastrelli, G., Comeglio, P., Guaraldi, F., Mazzatenta, D., Sforza, A., Vignozzi, L., & Maggi, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2144829 · Cited by 25
“Available guidelines indicate adding on TRT to DAT when the latter therapy alone is not able to completely restore normal T levels [82,83].”
BackgroundEndocrine factors associated with infertility in women: an updated review
Concepción‐Zavaleta, M. J., Arroyo, J., Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Ildefonso-Najarro, S. P., Rafael-Robles, L. D. P., Urteaga, L. A. C., Osorio, E. R. G., Suárez-Rojas, J., & Paz‐Ibarra, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256405 · Cited by 34
“nancy [189,190] in over 85% of cases after correcting hyperprolactinemia [191].”
BackgroundCastro, M. A., Marazuela, M., Puig‐Domingo, M., & Biagetti, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814002 · Cited by 26
“Transsphenoidal surgery is, in general, the first-line treatment selected for patients with secretory PitNETs, independently of size, except for lactotroph tumors [5], for which dopamine agonists (DA), mainly cabergoline, are the first choice.”
BackgroundAromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior
Akıncı, H., Kapucu, A., Dar, K. A., Celik, O., Tütüncüler, B., Şirin, G., Öz, B., Gazioğlu, N., İnce, H., Aliustaoğlu, S., et al. (2012) · Pituitary · doi:10.1007/s11102-012-0436-2 · Cited by 22
Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia
Abbara, A., Clarke, S. A., Nesbitt, A., Ali, S., Comninos, A. N., Hatfield, E., Martin, N. M., Sam, A. H., Meeran, K. M., & Dhillo, W. S. (2018) · Neuroendocrinology · doi:10.1159/000489264 · Cited by 25
Club, P. P., Barbot, M., Ceccato, F., Lizzul, L., Daniele, A., Zilio, M., Gardiman, M. P., Denaro, L., Emanuelli, E., Vianello, F., et al. (2019) · Neurosurgical Review · doi:10.1007/s10143-019-01132-1 · Cited by 22
Silva, J. F., Henriques, P. C., Campideli-Santana, A. C., Araújo-Lopes, R., Aquino, N. S. S., Hipolito, L. T. M., Lopes‐Aguiar, C., dos Reis, A. M., Grattan, D. R., & Szawka, R. E. (2020) · Endocrinology · doi:10.1210/endocr/bqaa022 · Cited by 22
Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications
Haidenberg-David, F., Sidauy-Adissi, J., Moscona-Nissan, A., Jonguitud-Zumaya, E., Fugarolas-Morinelli, M., Martínez-Mendoza, F., Taniguchi‐Ponciano, K., Marrero–Rodríguez, D., & Mercado, M. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103102 · Cited by 37
Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review
Penn, M., Cardinal, T. M., Zhang, Y., Abt, B. G., Bonney, P. A., Lorenzo, P., Lin, M. P., Rosner, J., Weiss, M. H., Zada, G., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab074 · Cited by 21
Pirchio, R., Auriemma, R. S., Solari, D., Arnesi, M., Pivonello, C., Negri, M., de Angelis, C., Cavallo, L. M., Cappabianca, P., Colao, A. A. L., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769744 · Cited by 21
“Notably, the expression of dopamine receptors type 2 (D2DR) on human pancreatic b-cells (13) and adipocytes (14) provided the rationale to investigate the effects of treatment with dopamine and dopamine agonists (DA), mainly bromocriptine (BRC) and cabergoline (CAB), known to represent the treatment of choice for pati…”
BackgroundACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway
Cai, L., Wu, Z., Cao, L., Lu, J., Lu, J.-L., Wang, C.-D., Jin, J.-H., Wu, Z. B., & Su, Z. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00856-5 · Cited by 23
“INTRODUCTION Pituitary adenoma is one of the most common intracranial neoplasms, and ~40% to 66% of all pituitary adenomas are prolactinomas [1, 2].”
BackgroundBashari, W. A., van der Meulen, M., MacFarlane, J., Gillett, D., Senanayake, R., Serban, L., Powlson, A., Brooke, A. M., Scoffings, D. J., Jones, J., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01229-9 · Cited by 21
“Traditonally, dopamine agonist therapy has been considered the cornerstone of management of patients with prolactinoma [5, 49].”
BackgroundMethodInfluentialPredicting hypogonadotropic hypogonadism persistence in male macroprolactinoma
Rudman, Y., Duskin‐Bitan, H., Masri‐Iraqi, H., Akirov, A., & Shimon, I. (2022) · Pituitary · doi:10.1007/s11102-022-01259-3 · Cited by 22
“Medical treatment with cabergoline is recommended as first-line therapy for patients with symptomatic prolactinomas [15].”
BackgroundUzuner, A., Yılmaz, E., Çaklılı, M., Selek, A., Aydemir, F., Çabuk, B., Anık, İ., & Ceylan, S. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.12.003 · Cited by 21
Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review
Junqueira, D. R., Bennett, D., Huh, S. Y., & Comabella, C. C. I. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00462-2 · Cited by 33
“Elevated PRL levels have been reported under certain physiological conditions, such as pregnancy or breastfeeding, stress, exercise, and anxiety [2, 6].”
BackgroundInfluentialHow to manage intolerance to dopamine agonist in patients with prolactinoma
Stumpf, M. A. M., Pinheiro, F. M. M., da Silva, G. O., Cescato, V. Â. S., Musolino, N. R. D. C., Cunha-Neto, M. B. C., & Glezer, A. (2023) · Pituitary · doi:10.1007/s11102-023-01313-8 · Cited by 21
Mel'nichenko, G. A., Dzeranova, L. K., Pigarova, E. A., Vorotnikova, S. Y., Рожинская, Л. Я., & Dedov, I. I. (2013) · Problems of Endocrinology · doi:10.14341/probl201359619-26 · Cited by 21
Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1
Gan, H., Bulwer, C., Jeelani, O., Levine, M. A., Korbonits, M., & Spoudeas, H. A. (2015) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-015-0011-5 · Cited by 21
“The mechanism for development of drug-resistance is not well understood, and is thought to relate to dopamine D2 receptor downregulation [7].”
BackgroundInfluentialLi, Q., Su, Z., Liu, J., Cai, L., Lu, J., Lin, S., Xiong, Z., Li, W., Zheng, W., Wu, J., et al. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.10.021 · Cited by 21
“However, 10–20% of prolactinomas are resistant to DAs treatment (Melmed et al., 2011; Molitch, 2005).”
Dopamine Agonist-Induced Impulse Control Disorders in a Patient with Prolactinoma
Almánzar, S. F., Zapata-Vega, M. I., & Raya, J. A. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.10.002 · Cited by 24
Watanabe, S., Akutsu, H., Takano, S., Yamamoto, T., Ishikawa, E., Suzuki, H., & Matsumura, A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13240 · Cited by 21
Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?
Petersenn, S., Christ‐Crain, M., Droste, M., Finke, R., Flitsch, J., Kreitschmann‐Andermahr, I., Luger, A., Schopohl, J., & Stalla, G. K. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0794-7587 · Cited by 24
“1 Recommendations on the treatment of prolactinoma in pregnancy, modified from [3,5,8].”
InfluentialEickholz, P., Kim, T., Schacher, B., Reitmeir, P., Bürklin, T., & Ratka‐Krüger, P. (2005) · PubMed · Cited by 21
Prolactinoma and pregnancy – a series of cases including pituitary apoplexy
Galvão, A., Gonçalves, D. R., Moreira, M., Inocêncio, G., Silva, C., & Braga, J. S. (2016) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2016.1233946 · Cited by 21
“…volume and serum prolactin level in non-pregnant patients, routine measurement of serum prolactin as a marker of tumour growth in pregnant patients is not recommended because of the very significant increase in the concentration of prolactin during pregnancy (Schlechte 2003; Melmed et al. 2011).”
BackgroundAlkabbani, A. G., Mon, S. Y., Hatipoğlu, B., Kennedy, L., Faiman, C., Weil, R. J., & Hamrahian, A. H. (2013) · Pituitary · doi:10.1007/s11102-013-0473-5 · Cited by 21
Diagnosis and management of prolactinomas: current challenges
Petersenn, S., & Giustina, A. (2020) · Pituitary · doi:10.1007/s11102-019-01025-y · Cited by 21
Liu, Y., Liu, F., Li, C., Zhang, T., Han, T., Dai, Y., Huang, N., Tang, H., Wang, X., Lin, S., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae241 · Cited by 23
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis
English, K. A., Pieterman, C. R. C., Marini, F., Lines, K. E., Cuny, T., Saulle, R., Shariq, O. A., Mitrova, Z., Castinetti, F., Waguespack, S. G., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00118-4 · Cited by 20
Evolución del microprolactinoma a largo plazo con tratamiento médico
Llanes, M. M. D. S.-O., Melero, V. M. A., & Albarrán, A. J. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.007 · Cited by 20
Nemes, A., Fortmann, T., Poeschke, S., Greve, B., Prevedello, D. M., Santacroce, A., Stummer, W., Senner, V., & Ewelt, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161364 · Cited by 22
“Treatment of choice for pituitary adenomas has traditionally been the transnasal, transsphenoidal surgical resection, either via microscope or endoscope, whereas in prolactinomas and selected patients with acromegaly, medical treatment is a well-established alternative [4,5].”
BackgroundEspinosa-Cárdenas, E., Sanchez-García, M. L., Ramírez‐Rentería, C., Mendoza‐Zubieta, V., Sosa, E., & Mercado, M. (2020) · Endocrine · doi:10.1007/s12020-020-02388-0 · Cited by 20
Current and Emerging Medical Therapies in Pituitary Tumors
Sahakian, N., Castinetti, F., Brue, T. C., & Cuny, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040955 · Cited by 22
Aldahmani, K. M., Almalki, M., Ekhzaimy, A. A., Aziz, F., Bashier, A. M., Mahzari, M. M., & Beshyah, S. (2022) · Pituitary · doi:10.1007/s11102-022-01242-y · Cited by 21
Herman, T., Csehely, S., Orosz, M., Bhattoa, H. P., Deli, T., Török, P., Laganà, A. S., Chiàntera, V., & Jakab, A. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-01137-0 · Cited by 23
Closure strategy for endoscopic pituitary surgery: Experience from 3015 patients
Baussart, B., Venier, A., Jouinot, A., Reuter, G., & Gaillard, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1067312 · Cited by 20
Maseroli, E., Verde, N., Cipriani, S., Rastrelli, G., Alfaroli, C., Ravelli, S. A., Costeniero, D., Scairati, R., Minnetti, M., Petraglia, F., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02101-8 · Cited by 23
“In addition, the diagnostic workflow for the pathological conditions was performed according to the current Endocrine Society guidelines [52].”
MethodPontes, J. P. M., Udoma‐Udofa, O. C., de Oliveira, J. S., Larcipretti, A. L. L., Dagostin, C. S., Gomes, F. C., Nager, G. B., & Bannach, M. D. A. (2023) · Pituitary · doi:10.1007/s11102-023-01332-5 · Cited by 26
Antipsychotic-Induced Hyperprolactinemia and Testosterone Levels in Boys
Roke, Y., van Harten, P. N., Buitelaar, J. K., Tenback, D. E., de Rijke, Y. B., & Boot, A. M. (2012) · Hormone Research in Paediatrics · doi:10.1159/000337910 · Cited by 22
Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans
Bernard, V., Bouilly, J., Beau, I., Broutin, I., Chanson, P., Young, J., & Binart, N. (2015) · Neuroendocrinology · doi:10.1159/000442981 · Cited by 20
Papanastasiou, L., Fountoulakis, S., Παππά, Θ., Liberopoulos, K., Malliopoulos, D., Markou, Α., & Piaditis, G. P. (2014) · HORMONES · doi:10.1007/bf03401344 · Cited by 20
“Surgery is limited to cases of intolerance or resistance to DA or when acute complications, such as sudden visual impairment, occur.(2,3,8)”
BackgroundAljabri, K. S., Bokhari, S., Assiri, F., Alshareef, M. A. U., & Khan, P. M. (2016) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2016.341 · Cited by 20
Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas
Geng, X., Ma, L., Li, Z., Li, Z., Li, J., Li, M., Wang, Q., Chen, Z., & Sun, Q. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.01.052 · Cited by 20
Elenkova, A. P., Atanasova, I., Кirilov, G., Natchev, Е., Ivanova, R., Kovatcheva, R. D., Vandeva, S., Tcharaktchiev, D., & Zacharieva, S. (2017) · Endocrine · doi:10.1007/s12020-017-1372-8 · Cited by 20
Prolactin and Its Role in Human Reproduction
Tritos, N. A., & Klibanski, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00003-2 · Cited by 38
Liu, Y., Zhang, Z., Jin, Q., Liu, Y., Kang, Z., Huo, Y., He, Z., Xu, F., Yin, J., Wu, X., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01896-y · Cited by 21
Yang, A., Cho, S. Y., Park, H., Kim, M. S., Kong, D., Shin, H.-J., & Jin, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00527 · Cited by 24
Puberty in the Female and Its Disorders
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00016-6 · Cited by 36
Yedinak, C. G., Cetas, I., Ozpinar, A., McCartney, S., Dog⫧an, A., & Fleseriu, M. (2016) · Endocrine · doi:10.1007/s12020-016-1042-2 · Cited by 20
Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective Study
Tsur, A., Dreyfuss, E., Ness-Abramof, R., Pollack, R. M., & Cahn, A. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0260 · Cited by 19
Besag, F., Vasey, M. J., & Salim, I. (2021) · CNS Drugs · doi:10.1007/s40263-021-00812-1 · Cited by 28
Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature
Kuhn, E., Weinreich, A. A., Biermasz, N. R., Jørgensen, J. O. L., & Chanson, P. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0145 · Cited by 23
Hyperprolactinemia after menopause: Diagnosis and management
Auriemma, R. S., Pirchio, R., Pivonello, R., & Colao, A. A. L. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.06.014 · Cited by 19
Ke, X., Wang, L., Chen, M., Liu, S., Yu, N., Duan, L., Gong, F., & Zhu, H. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01009-3 · Cited by 19
“Treatment with DAs can cause many different side effects, such as nausea, vomiting, orthostatic hypotension, and headache [6, 12, 15], that may be related to 5-HT1 receptors or D1 receptors.”
BackgroundRefractory lactotroph adenomas
Urwyler, S. A., & Karavitaki, N. (2023) · Pituitary · doi:10.1007/s11102-023-01305-8 · Cited by 19
“Overall, resistance to bromocriptine has been reported in 20–30% of the cases and to cabergoline in 10% of them [1, 3].”
BackgroundInfluentialItalian Guidelines for the Management of Prolactinomas
Cozzi, R. C., Auriemma, R. S., Menis, E. D., Esposito, F., Ferrante, E., Iatì, G., Mazzatenta, D., Poggi, M., Rudà, R., Tortora, F., et al. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230511104045 · Cited by 25
“DA drugs have been used successfully in the majority of cases, while neurosurgery has been progressively reserved for a minority of patients, namely those intolerant or resistant to pharmacological therapy and those with aggressive tumors [7].”
BackgroundHajjo, R., Momani, E., Sabbah, D. A., Baker, N., & Tropsha, A. (2023) · npj Vaccines · doi:10.1038/s41541-023-00719-6 · Cited by 22
“The fi rst column “ id ” lists the gene symbols of prioritized causal genes and vaccine-induced DEGs that are known as also biomarkers for menstrual cycle according to the CDDI database 46 . conditions like prolactinoma (noncancerous tumor of the pituitary gland) 74,79 – 81 .”
MethodA comprehensive review of the new FIGO classification of ovulatory disorders
Balen, A. H., Tamblyn, J. A., Skorupskaite, K., & Munro, M. G. (2024) · Human Reproduction Update · doi:10.1093/humupd/dmae003 · Cited by 26
Faje, A. T., & Klibanski, A. (2014) · Endocrine · doi:10.1007/s12020-014-0308-9 · Cited by 19
Huang, Y., Ding, C., Zhang, F., Xiao, D., Zhao, L. B., & Wang, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.7462 · Cited by 19
First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors
Deutschbein, T., Jaursch-Hancke, C., Knappe, U. J., Saeger, W., Flitsch, J., Bojunga, J., Buchfelder, M., Ditzen, B., Gerlach, R., Gertzen, E., et al. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1373-4087 · Cited by 21
Cabergoline Associated with First Episode Mania
Harris, Y., Harris, A. Z., deAsis, J. M., Ferrando, S. J., Reddy, N., & Young, R. C. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.01.005 · Cited by 20
“The Endocrine Society clinical practice guidelines recommend treating symptomatic microprolactinomas using dopamine agonists as first-line treatment.(47) Cabergoline is preferred over bromocriptine as it is more effective at decreasing prolactin levels and tumor size.”
InfluentialTreatment of Prolactinomas in Low-Income Countries
Kruljac, I., Kirigin, L. S., Strinović, M., Marinković, J., Pećina, H. I., Čerina, V., Stipić, D., & Vrkljan, M. (2015) · International Journal of Endocrinology · doi:10.1155/2015/697065 · Cited by 18
“Risks of pituitary surgery include hypopituitarism, diabetes insipidus, cerebrospinal fluid leaks, and infection [2].”
BackgroundInfluentialThe Effect of Raloxifene on Serum Prolactin Level in Patients with Prolactinoma
Choudhary, C., Hamrahian, A. H., Bena, J., Recinos, P. F., Kennedy, L., & Dobri, G. A. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0321 · Cited by 19
Resolution of headache after reduction of prolactin levels in hyperprolactinemic patients
Oliveira, M. D. C., Barea, L. M., Andreia Peres Klein, H. O. R. N., Ongaratti, B. R., Soares, J. O. D., de Araújo, B. M. F., dos Santos, T. M., Leães, C. G. S., & Pereira‐Lima, J. F. S. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190143 · Cited by 18
Increased Prolactin is an Adaptive Response to Protect Against Metabolic Disorders in Obesity
Liu, J., Wang, Q., Zhang, L., Fu, J., An, Y., Meng, H., & Wang, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.002 · Cited by 19
Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery
de Vries, F., Lobatto, D. J., Verstegen, M. J. T., Schutte, P. J., Notting, I. C., Kruit, M. C., Ahmed, S. F., Pereira, A. M., van Furth, W. R., & Biermasz, N. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab138 · Cited by 21
Hu, Y., Ni, J., Zhang, B., Cheng, W., Zhang, H., Ye, H., Ji, L., Lü, B., & Guan, M. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00861-z · Cited by 18
Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis
Lu, J., Cai, L., Wu, Z., Lin, W., Xu, J., Zhu, Z., Wang, C., Li, Q., & Su, Z. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9930059 · Cited by 18
A Link Between Migraine and Prolactin: the Way Forward
Gazerani, P. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0047 · Cited by 22
Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?
Stuenkel, C. A., Gompel, A., Davis, S. R., Pinkerton, J. V., Lumsden, M. A., & Santen, R. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab766 · Cited by 23
Prolactinoma: Clinical Characteristics, Management and Outcome
Irfan, H., Shafiq, W., Siddiqi, A. I., Ashfaq, S., Attaullah, S., Alvi, A. M., Khan, S. A., Bakar, M. A., & Azmat, U. (2022) · Cureus · doi:10.7759/cureus.29822 · Cited by 18
“Magnetic resonance imaging (MRI) with pituitary protocol is the gold standard protocol to look for the size and dimensions of adenoma and invasion of surrounding structures.”
BackgroundInfluentialThe use of hormone stimulation in male infertility
Foran, D., Chen, R., Jayasena, C. N., Minhas, S., & Tharakan, T. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102333 · Cited by 20
Macroprolactinemia: a mini-review and update on clinical practice
Koniares, K. G., Benadiva, C. A., Engmann, L., NULSEN, J. C., & Grow, D. R. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.05.005 · Cited by 18
“This is supported by the Endocrine Society’s recommendation to assess for macroprolactinemia in patients with asymptomatic hyperprolactinemia (21).”
The treatment of aggressive prolactinomas with everolimus
Lin, A. L., Geer, E. B., Lala, N., Page‐Wilson, G., Magge, R., Young, R. J., & Tabar, V. S. (2023) · Pituitary · doi:10.1007/s11102-023-01340-5 · Cited by 18
“The small subset of prolactinomas that grow despite surgery and radiotherapy have a single guideline supported medical therapy based on retrospective data supporting its use—treatment with the oral alkylator chemotherapy, temozolomide [1].”
BackgroundGoyal, A., & Ganie, M. A. (2018) · Cureus · doi:10.7759/cureus.3004 · Cited by 21
Lachowicz, E., & Lubiński, W. (2018) · Documenta Ophthalmologica · doi:10.1007/s10633-018-9659-5 · Cited by 22
Fertility issues in aggressive pituitary tumors
Marques, J. V. O., & Boguszewski, C. L. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09530-y · Cited by 18
“Furthermore, failure to restore fertility may also be reflective of treatment resistance [12].”
BackgroundInfluentialHypeprolactinemia: still an insidious diagnosis
Aliberti, L. M., Gagliardi, I., Dorizzi, R. M., Pizzicotti, S., Bondanelli, M., Zatelli, M. C., & Ambrosio, M. R. (2020) · Endocrine · doi:10.1007/s12020-020-02497-w · Cited by 18
Zandbergen, I. M., Najafabadi, A. H. Z., Pelsma, I. C. M., Marle, M. E. V. D. A., Bisschop, P. H. L. T., Boogaarts, H. D., van Bon, A. C., Burhani, B., le Cessie, S., Dekkers, O. M., et al. (2021) · Trials · doi:10.1186/s13063-021-05604-y · Cited by 20
“Prolonged DA treatment for prolactinoma, which is current standard practice [1, 4, 5], is very effective in controlling hyperprolactinaemia and restoring gonadal function.”
BackgroundInfluentialMahboobifard, F., Rahmati, M., Amiri, M., Azizi, F., & Tehrani, F. R. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2021.12.003 · Cited by 28
Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia
Pereira, A. M. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328347c94a · Cited by 18
Treatment of hyperprolactinemia in post-menopausal women: pros
Iacovazzo, D., & Marinis, L. D. (2014) · Endocrine · doi:10.1007/s12020-014-0377-9 · Cited by 18
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
Indirli, R., Ferrante, E., Sala, E., Giavoli, C., Mantovani, G., & Arosio, M. (2019) · Hormones and Cancer · doi:10.1007/s12672-019-00363-4 · Cited by 19
Prolactin's paradox: Friend, foe, or both in immune regulation?
Borba, V. V., Carrera‐Bastos, P., Zandman‐Goddard, G., Lucía, A., & Shoenfeld, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103643 · Cited by 20
Castro, M. A., Corrales, E. P., Cancela, A. A., Duque, S. G., Urzaiz, L. L., & Berrocal, V. R. (2020) · Endocrine · doi:10.1007/s12020-020-02455-6 · Cited by 16
Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
Lyu, L., Yin, S., Hu, Y., Chen, C., Jiang, Y., Yu, Y., Ma, W., Wang, Z., Jiang, S., & Zhou, P. (2020) · Medicine · doi:10.1097/md.0000000000022673 · Cited by 20
“was based on a PRL level upgrading above the upper limit of normal range.([20]) Other hormones, including cortisol, adrenocorticotropic hormone (ACTH), free tetraiodothyronine (FT4), free triiodothyronine (FT3), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol,…”
Changes in complete blood count parameters influenced by endocrine disorders
Szczepanek‐Parulska, E., Adamska, M., Korda, O., Kosicka, W., Skowrońska, D., Świejkowska, A., Tuzimek, D., Dadej, D., Krygier, A., & Ruchała, M. A. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0059 · Cited by 21
The utility of rested prolactin sampling in the evaluation of hyperprolactinaemia
Wilkinson, T., Li, B., Soule, S. G., & Hunt, P. J. (2023) · Internal Medicine Journal · doi:10.1111/imj.16208 · Cited by 17
Han, T. S., Antonio, L., Bártfai, G., O’Neill, T. W., Punab, M., Rastrelli, G., Maggi, M., Słowikowska‐Hilczer, J., Tournoy, J., Vanderschueren, D., et al. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09890-0 · Cited by 17
Self-citationWang, C., Lu, Y., Ou, M., Qian, L., Zhang, Y., Yang, Y., Luo, L., & Wang, Q. (2025) · Human Reproduction · doi:10.1093/humrep/deaf042 · Cited by 22
Chronic anovulation and the polycystic ovary syndrome
KASE, N. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003254.012 · Cited by 16
Late presentation of acromegaly in medically controlled prolactinoma patients
Manuylova, E., Calvi, L. M., Hastings, C., Vates, G. E., Johnson, M. D., Cave, W. T., & Shafiq, I. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0069 · Cited by 17
Cabergoline‐related impulse control disorder in an adolescent with a giant prolactinoma
Bulwer, C., Conn, R., Shankar, A., Ferraù, F., Kapur, S., Ederies, A., Korbonits, M., & Spoudeas, H. A. (2017) · Clinical Endocrinology · doi:10.1111/cen.13339 · Cited by 18
Disorders of Prolactin Secretion and Prolactinomas
Bronstein, M. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00007-x · Cited by 20
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Mahboobifard, F., Bidari‐Zerehpoosh, F., Davoudi, Z., Panahi, M., Dargahi, L., Pourgholami, M. H., Sharifi, G., Izadi, N., & Jorjani, M. (2020) · Pituitary · doi:10.1007/s11102-020-01029-z · Cited by 20
Özkaya, H. M., Şahin, S., Korkmaz, Ö. P., Durcan, E., Sahin, H. R., Çelik, E., Poyraz, B. Ç., & Kadıoğlu, P. (2020) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2020.101356 · Cited by 17
Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated
Andereggen, L., Frey, J., & Christ, E. (2020) · Endocrine · doi:10.1007/s12020-020-02557-1 · Cited by 17
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.